TY - JOUR
T1 - Understanding the role of cessation fatigue in the smoking cessation process
AU - Liu, Xiaoyu
AU - Li, Runze
AU - Lanza, Stephanie T.
AU - Vasilenko, Sara A.
AU - Piper, Megan
N1 - Funding Information:
This project was supported by Award Numbers P50-DA010075-15 , P50 DA019706 , P50-DA0197 and T32-DA017629 from the National Institute on Drug Abuse (NIDA) , P50-CA84724 and R01 CA168676 from the National Cancer Institute (NCI) , and M01-RR03186 from The General Clinical Research Centers Program of the National Center for Research Resources .
PY - 2013/12/1
Y1 - 2013/12/1
N2 - Background: To understand the dynamic process of cessation fatigue (i.e., the tiredness of trying to quit smoking) with respect to its average trend, effect on relapse, time-varying relations with craving and negative affect, and differences among genders and treatment groups. Method: Randomized placebo-controlled clinical trial. Participants received either placebo, monotherapy (bupropion SR, nicotine patch, nicotine lozenge), or combined pharmacotherapy (bupropion SR. +. nicotine lozenge, nicotine patch. +. nicotine lozenge). Data were collected from 1504 daily smokers who were motivated to quit smoking. The participants completed baseline assessments and ecological momentary assessments for 2 weeks post-quit. Results: Cessation fatigue reduced the likelihood of 6-month post-quit abstinence (OR. = 0.97, 95% CI (0.95, 0.99)), and was positively associated with craving and negative affect. After controlling for these two factors, average cessation fatigue increased over time. Compared to men, women experienced greater fatigue (t= -10.69, p<. 0.0001) and a stronger relation between fatigue and craving (t= -8.80, p<. 0.0001). The relationship between fatigue and negative affect was significantly stronger in men (t= 5.73, p<. 0.0001). Cessation fatigue was significantly reduced by combined pharmacotherapy (t= -13.4, p<. 0.0001), as well as monotherapy (t= -6.2, p<. 0.0001). Conclusions: Cessation fatigue was closely related to craving, negative affect, and cessation outcomes. Women reported greater cessation fatigue than men. Current treatments appeared to reduce fatigue and weaken its relations with craving and negative affect.
AB - Background: To understand the dynamic process of cessation fatigue (i.e., the tiredness of trying to quit smoking) with respect to its average trend, effect on relapse, time-varying relations with craving and negative affect, and differences among genders and treatment groups. Method: Randomized placebo-controlled clinical trial. Participants received either placebo, monotherapy (bupropion SR, nicotine patch, nicotine lozenge), or combined pharmacotherapy (bupropion SR. +. nicotine lozenge, nicotine patch. +. nicotine lozenge). Data were collected from 1504 daily smokers who were motivated to quit smoking. The participants completed baseline assessments and ecological momentary assessments for 2 weeks post-quit. Results: Cessation fatigue reduced the likelihood of 6-month post-quit abstinence (OR. = 0.97, 95% CI (0.95, 0.99)), and was positively associated with craving and negative affect. After controlling for these two factors, average cessation fatigue increased over time. Compared to men, women experienced greater fatigue (t= -10.69, p<. 0.0001) and a stronger relation between fatigue and craving (t= -8.80, p<. 0.0001). The relationship between fatigue and negative affect was significantly stronger in men (t= 5.73, p<. 0.0001). Cessation fatigue was significantly reduced by combined pharmacotherapy (t= -13.4, p<. 0.0001), as well as monotherapy (t= -6.2, p<. 0.0001). Conclusions: Cessation fatigue was closely related to craving, negative affect, and cessation outcomes. Women reported greater cessation fatigue than men. Current treatments appeared to reduce fatigue and weaken its relations with craving and negative affect.
KW - Cessation fatigue
KW - Ecological momentary assessments
KW - Smoking cessation
KW - Time-varying effect model
UR - http://www.scopus.com/inward/record.url?scp=84887017298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887017298&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2013.07.025
DO - 10.1016/j.drugalcdep.2013.07.025
M3 - Article
C2 - 23954071
AN - SCOPUS:84887017298
SN - 0376-8716
VL - 133
SP - 548
EP - 555
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
IS - 2
ER -